Literature DB >> 23876344

Dancing with chemical formulae of antivirals: a personal account.

Erik De Clercq1.   

Abstract

A chemical structure is a joy forever, and this is how I perceived the chemical structures of a number of antiviral compounds with which I have been personally acquainted over the past 3 decades: (1) amino acid esters of acyclovir (i.e. valaciclovir); (2) 5-substituted 2'-deoxyuridines (i.e. brivudin); (3) 2',3'-dideoxynucleoside analogues (i.e. stavudine); (4) acyclic nucleoside phosphonates (ANPs) (i.e. cidofovir, adefovir); (5) tenofovir disoproxil fumarate (TDF) and drug combinations therewith; (6) tenofovir alafenamide (TAF, GS-7340), a new phosphonoamidate prodrug of tenofovir; (7) pro-prodrugs of PMEG (i.e. GS-9191 and GS-9219); (8) new ANPs: O-DAPy and 5-aza-C phosphonates; (9) non-nucleoside reverse transcriptase inhibitors (NNRTIs): HEPT and TIBO derivatives; and (10) bicyclam derivatives (i.e. AMD3100).
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  2′,3′-Dideoxynucleoside (ddN) analogues; Acyclic nucleoside phosphonates; Bicyclam (AMD3100) derivatives; Bromovinyldeoxyuridine; GS-9191, GS-9219, cPrPMEDAP, and PMEG; HEPT and TIBO derivatives; O-DAPy and 5-azaC phosphonate analogues; Tenofovir alafenamide (GS-7340); Tenofovir disoproxil fumarate (TDF); Valaciclovir

Mesh:

Substances:

Year:  2013        PMID: 23876344     DOI: 10.1016/j.bcp.2013.07.012

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Impact of the 2'- and 3'-Sugar Hydroxyl Moieties on Gas-Phase Nucleoside Structure.

Authors:  L A Hamlow; Zachary J Devereaux; H A Roy; N A Cunningham; G Berden; J Oomens; M T Rodgers
Journal:  J Am Soc Mass Spectrom       Date:  2019-03-08       Impact factor: 3.109

Review 2.  Current and future directions for treating hepatitis B virus infection.

Authors:  Akinobu Tawada; Tatsuo Kanda; Osamu Yokosuka
Journal:  World J Hepatol       Date:  2015-06-18

Review 3.  An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014.

Authors:  Erik De Clercq
Journal:  Acta Pharm Sin B       Date:  2015-11-02       Impact factor: 11.413

Review 4.  N-Pyrrylarylsulfones with High Therapeutic Potential.

Authors:  Valeria Famiglini; Sabrina Castellano; Romano Silvestri
Journal:  Molecules       Date:  2017-03-09       Impact factor: 4.411

Review 5.  Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines.

Authors:  Annoor Awadasseid; Yanling Wu; Yoshimasa Tanaka; Wen Zhang
Journal:  Biomed Pharmacother       Date:  2021-01-28       Impact factor: 7.419

Review 6.  Newly Emerging Strategies in Antiviral Drug Discovery: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Anniversary.

Authors:  Shujing Xu; Dang Ding; Xujie Zhang; Lin Sun; Dongwei Kang; Boshi Huang; Xinyong Liu; Peng Zhan
Journal:  Molecules       Date:  2022-01-27       Impact factor: 4.411

Review 7.  Indolylarylsulfones, a fascinating story of highly potent human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.

Authors:  Valeria Famiglini; Romano Silvestri
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

Review 8.  New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections.

Authors:  Erik De Clercq
Journal:  Chem Asian J       Date:  2019-08-07

9.  Novel Thiazolidin-4-ones as Potential Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase.

Authors:  Anthi Petrou; Phaedra Eleftheriou; Athina Geronikaki; Melpomeni G Akrivou; Ioannis Vizirianakis
Journal:  Molecules       Date:  2019-10-23       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.